Treace Medical Concepts (TMCI) Depreciation & Amortization (CF) (2020 - 2026)

Treace Medical Concepts' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $899000.0 for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 63.47% year-over-year to $899000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 1.0% YoY) and the FY2025 annual result came in at $10.6 million, up 26.18% from the prior year.
• Depreciation & Amortization (CF) was $899000.0 for Q1 2026 at Treace Medical Concepts, down from $2.8 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.8 million in Q4 2025 and bottomed at $334000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 300.0% — and 2026, when it tumbled 63.47%.
• Treace Medical Concepts' Depreciation & Amortization (CF) stood at $917000.0 in 2022, then jumped by 92.91% to $1.8 million in 2023, then advanced by 26.46% to $2.2 million in 2024, then advanced by 25.53% to $2.8 million in 2025, then sank by 67.98% to $899000.0 in 2026.
• Business Quant data shows TMCI's Depreciation & Amortization (CF) at $899000.0 in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.